welcome  malin plc menu homeaboutdirectorsboard committeesadvisorsbusinessesdmedicalaltan pharmaanh discoveryartizan biosciencescilatus biopharmahatteras venture partners hvpimmunocorejaan healthknow biokymabmelinta therapeuticsneuvtnovanposeida therapeuticsserenusviamet pharmaceuticalswren therapeuticsxenex disinfection servicesnewsmalin rns announcementsinvestee company newsinvestorsshareholder centrereports  resultspfic statusesm rule corporate governance  constitutional documentsinvestor relations contactanalyst coveragecontact annual reportfind out more malin corporation plc isemlc “malin” is an irish incorporated public limited company whose head office is in dublin ireland with subsidiary offices in new haven connecticut usa and cambridge united kingdom malin’s purpose is to create shareholder value through the selective longterm application of capital and operational expertise to private preipo pretrade sale operating businesses in dynamic and fast growing segments of the life sciences industry through its operational involvement malin works with its investee companies to enable them to reach the full potential of their value proposition and to achieve commercial success  jul  directorpdmr shareholding  jul  directorpdmr shareholding  jul  appointment of new board member  jun  result of agm  jun  directorpdmr shareholding  jun  directorpdmr shareholding  jun  novan leadership adjustments  jun  publication of annual report  notice of agm  may  directorpdmr shareholding  may  holdings in company  may  directorpdmr shareholding  may  block listing interim review  may  result of placing  apr  fundraising intention  apr  directorpdmr shareholding  apr  directorpdmr shareholding  apr  directorpdmr shareholding  mar  directorpdmr shareholding  feb  investment in artizan biosciences  jan  investment in wren therapeutics  jan  investment in cilatus biopharma  jan  directorpdmr shareholding  dec  directorpdmr shareholding  dec  directorate change  nov  directorpdmr shareholding  nov  block listing interim review  oct  senior management appointment  sep  ipo of novan inc  sep  half yearly report  aug  board change  aug  holdings in company  aug  directorpdmr shareholding  jul  directorpdmr shareholding  jul  directorpdmr shareholding  jun  eib debt facility  jun  eib debt facility  may  director dealings  may  issue of equity and director dealing  may  directors interest notification  replacement  may  director dealings  may  directors interests notification  may  block listing interim review  apr  holdings in company  apr  result of agm and director retirement  apr  publication of annual report  notice of agm  jan  director dealings  jan  director dealings  jan  director dealings  jan  holdings in company  jan  director dealings  jan  director dealings  dec  director dealings  dec  director dealing  dec  investment in poseida therapeutics  dec  further regulatory disclosures  dec  appointment of new board member  nov  issue of equity and director dealing  nov  block admission application  directors interests  sep  issue of equity  director dealing  sep  half yearly report  aug  acquisition phase completion  aug  holdings in company  jul  holdings in company  jul  results of placing  jul  placing announcement  jul  investment in immunocore  jul  investment in d medical  jun  investment in altan pharma  jun  investment in melinta therapeutics  jun  holdings in company  may  holdings in company  may  completion of additional investment  mar  holdings in company  mar  enterprise securities market notice  mar  first day of dealings  mar  results of placing  mar  esm schedule  update  feb  esm schedule  malin rns announcements view all rns announcements investee company news july   novan announces corporate update conference call and webcast july   fda grants fast track designation to vt for treatment of valley fever view all news items we use cookies to give you the best experience on our website if you continue without changing your cookie settings we assume that you consent to our use of cookies on this device you can change your cookie settings at any time but if you do you may lose some functionality on our website more information can be found in our cookie policy close malin plc » contact menu homeaboutdirectorsboard committeesadvisorsbusinessesdmedicalaltan pharmaanh discoveryartizan biosciencescilatus biopharmahatteras venture partners hvpimmunocorejaan healthknow biokymabmelinta therapeuticsneuvtnovanposeida therapeuticsserenusviamet pharmaceuticalswren therapeuticsxenex disinfection servicesnewsmalin rns announcementsinvestee company newsinvestorsshareholder centrereports  resultspfic statusesm rule corporate governance  constitutional documentsinvestor relations contactanalyst coveragecontact contact your name your email your message  contact details ireland malin corporation plc  harbour square dun laoghaire co dublin ireland a dr general main switch telephone   fax   emailinfomalinplccom media relationsinvestor relations telephone   emailmediarelationsmalinplccom united states malin life sciences us inc  church street floor  new haven ct  usa main switch telephone   fax    united kingdom malin life sciences uk ltd rd floor bateman house    hills road cambridge cb lq united kingdom main switch telephone    we use cookies to give you the best experience on our website if you continue without changing your cookie settings we assume that you consent to our use of cookies on this device you can change your cookie settings at any time but if you do you may lose some functionality on our website more information can be found in our cookie policy close malin plc » investee company news menu homeaboutdirectorsboard committeesadvisorsbusinessesdmedicalaltan pharmaanh discoveryartizan biosciencescilatus biopharmahatteras venture partners hvpimmunocorejaan healthknow biokymabmelinta therapeuticsneuvtnovanposeida therapeuticsserenusviamet pharmaceuticalswren therapeuticsxenex disinfection servicesnewsmalin rns announcementsinvestee company newsinvestorsshareholder centrereports  resultspfic statusesm rule corporate governance  constitutional documentsinvestor relations contactanalyst coveragecontact investee company news july   novan announces corporate update conference call and webcast july   fda grants fast track designation to vt for treatment of valley fever july   surgical specialty center of baton rouge is first hospital in southern louisiana to enhance patient safety by deploying a xenex lightstrike germzapping robot july   novan to present safety and efficacy data for sb program in adolescents at th world congress of pediatric dermatology july   immunocore and mepc announce significant laboratory expansion at milton park in oxfordshire uk july   immunocore announces third oncology target selected in discovery collaboration with glaxosmithkline june   melinta signs  million financing agreement with oberland capital to fund baxdela™ commercial activities and expansion into additional indications june   viamet to present data on vt for the treatment of onychomycosis at the th international summit on nail diseases june   melinta therapeutics announces us fda approval of baxdela™ delafloxacin for acute bacterial skin and skin structure infections absssi june   kymab appoints dr martin nicklasson as nonexecutive chair june   viamet to participate in antifungal panel discussion at the  bio international convention june   xenex announces lightstrike disinfection pod™ – industry’s first mobile equipment disinfection system june   dmedical announces exclusive partnership with sky june   melinta therapeutics demonstrates potential of pyrrolocytosine candidate against gonorrhea june   novan announces leadership adjustments and business update june   viamet’s vt demonstrates potent activity against candida auris and other lifethreatening fungal species june   poseida therapeutics presents highfidelity genome editing system for production of allogeneic “universal donor” cart cells at american society of clinical oncology annual meeting june   immunocore announces compelling single agent imcgp clinical data in metastatic uveal melanoma at asco  annual meeting june   viamet presents phase b results demonstrating unprecedented efficacy of oral vt in the treatment of recurrent vulvovaginal candidiasis june   melinta therapeutics presenting in vivo and in vitro results from baxdela studies at asm microbe june   immunocore highlights imcgp clinical data in uveal melanoma at asco  annual meeting may   teneobio and poseida announce license agreement for the use of unidab™ in car tcell therapy may   viamet data for vt and vt to be presented at the american society for microbiology’s asm microbe  conference may   novan reports first quarter  financial results may   abbas hussain joins the board of immunocore as nonexecutive director may   dmedical launches complete ortho – its latest clinical app for iphone and ipad may   kymab appoints dr sonia quaratino as chief medical officer may   immunocore identifies second novel immtac® in the gsk collaboration may   melinta therapeutics’ phase  trials of baxdela document challenges in antibiotic selection in patients treated for absssi april   novan presents safety data for sb program in this section malin rns announcements investee company news we use cookies to give you the best experience on our website if you continue without changing your cookie settings we assume that you consent to our use of cookies on this device you can change your cookie settings at any time but if you do you may lose some functionality on our website more information can be found in our cookie policy close malin plc » pfic status menu homeaboutdirectorsboard committeesadvisorsbusinessesdmedicalaltan pharmaanh discoveryartizan biosciencescilatus biopharmahatteras venture partners hvpimmunocorejaan healthknow biokymabmelinta therapeuticsneuvtnovanposeida therapeuticsserenusviamet pharmaceuticalswren therapeuticsxenex disinfection servicesnewsmalin rns announcementsinvestee company newsinvestorsshareholder centrereports  resultspfic statusesm rule corporate governance  constitutional documentsinvestor relations contactanalyst coveragecontact pfic status information for us shareholders we have concluded that malin corporation plc is a passive foreign investment company “pfic” for us federal income tax purposes for the year ended december   the below information statement has been provided to allow you to complete a form  and make a qualifying electing fund “qef” election should you choose to do so  malin corporation plc  information statements as a company’s pfic status for a given tax year will not be determinable until the close of that year no determination can be made at this point in time with regard to pfic status in any future year this information does not constitute tax advice and we encourage you to consult with your tax advisor with respect to the treatment of your shareholdings for us tax purposes and to provide them with the attached information statement    statement  malin corporation plc  information statements in this section shareholder centre reports  results pfic status esm rule  corporate governance  constitutional documents investor relations contact analyst coverage we use cookies to give you the best experience on our website if you continue without changing your cookie settings we assume that you consent to our use of cookies on this device you can change your cookie settings at any time but if you do you may lose some functionality on our website more information can be found in our cookie policy close malin plc » advisors menu homeaboutdirectorsboard committeesadvisorsbusinessesdmedicalaltan pharmaanh discoveryartizan biosciencescilatus biopharmahatteras venture partners hvpimmunocorejaan healthknow biokymabmelinta therapeuticsneuvtnovanposeida therapeuticsserenusviamet pharmaceuticalswren therapeuticsxenex disinfection servicesnewsmalin rns announcementsinvestee company newsinvestorsshareholder centrereports  resultspfic statusesm rule corporate governance  constitutional documentsinvestor relations contactanalyst coveragecontact advisors details address website esm adviser  broker davy davy house  dawson street dublin  ireland wwwdavyie legal advisers to the company al goodbody ifsc north wall quay dublin  ireland wwwalgoodbodycom reporting accountants and auditors to the company kpmg  stokes place st stephen’s green dublin  ireland wwwkpmgcom registrar computershare investor services ireland heron house corrig road sandyford industrial estate dublin  ireland wwwcomputersharecom in this section directors board committees advisors we use cookies to give you the best experience on our website if you continue without changing your cookie settings we assume that you consent to our use of cookies on this device you can change your cookie settings at any time but if you do you may lose some functionality on our website more information can be found in our cookie policy close malin plc » admission document disclaimer menu homeaboutdirectorsboard committeesadvisorsbusinessesdmedicalaltan pharmaanh discoveryartizan biosciencescilatus biopharmahatteras venture partners hvpimmunocorejaan healthknow biokymabmelinta therapeuticsneuvtnovanposeida therapeuticsserenusviamet pharmaceuticalswren therapeuticsxenex disinfection servicesnewsmalin rns announcementsinvestee company newsinvestorsshareholder centrereports  resultspfic statusesm rule corporate governance  constitutional documentsinvestor relations contactanalyst coveragecontact admission document disclaimer electronic versions of the materials you are seeking to access are being made available on this webpage by malin corporation plc in good faith and for information purposes only these materials are not directed at or accessible by persons located in the united states canada japan south africa or australia us persons or persons in any other jurisdiction where the distribution of these materials would breach any applicable law or regulation or would require any registration or licensing within such jurisdiction please read this notice carefully – it applies to all persons who view this webpage please note that the disclaimer set out below may be altered or updated you should read it in full each time you visit the site viewing the materials you are seeking to access may not be lawful in certain jurisdictions in other jurisdictions only certain categories of person may be allowed to view such materials any persons who wish to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so the information in the following pages is not intended for and is not to be made available to persons in the united states canada japan south africa or australia or to us persons any announcements regarding securities offerings or references to securities offerings that are contained on these pages do not constitute an offering of those securities any offering of securities will be contained in a prospectus or other offering circular or memorandum that contains detailed information about the issuer and the offered securities including a discussion of risks the issuer’s business and relevant financial information any securities referred to in these materials have not been and will not be registered under the us securities act of  as amended the “securities act” or under the securities laws of any state or other jurisdiction of the united states and may not be offered sold or delivered directly or indirectly in or into the united states or to or for the account or benefit of us persons as defined in regulation s under the securities act “regulation s” except pursuant to an exemption from or in a transaction not subject to the registration requirements of the securities act and in compliance with any applicable securities laws of any state or other jurisdiction of the united states and under circumstances that would not require malin corporation plc to register under the us investment company act of  as amended there will be no public offer of securities in the united states any securities referred to in these materials have not been and will not be registered under the securities laws of canada japan south africa or australia and may not be offered sold or delivered directly or indirectly within such jurisdictions except pursuant to an applicable exemption from and in compliance with any applicable securities laws if you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials please exit this webpage these materials must not be released or otherwise forwarded distributed or sent directly or indirectly in whole or in part in or into the united states canada japan south africa or australia or any jurisdiction where the distribution of these materials would breach any applicable law or regulation or would require any registration or licensing within such jurisdiction or to any us person basis of access access to electronic versions of these materials is being made available on this webpage by malin corporation plc in good faith and for information purposes only any person seeking access to this webpage represents and warrants to malin corporation plc that they are doing so for information purposes only making press announcements and other documents available in electronic format does not constitute an offer to sell or the solicitation of an offer to buy securities in malin corporation plc further it does not constitute a recommendation by malin corporation plc or any other party to sell or buy securities in malin corporation plc confirmation of understanding and acceptance of disclaimer by clicking on the “i agree” button i warrant that i am not resident or located in the united states canada japan south africa or australia or any other jurisdiction where accessing these materials is unlawful and am not a us person as defined in regulation s and i agree that i will not transmit or otherwise send any materials contained in this website to any person in the united states canada japan south africa or australia or any other territory where to do so would breach any applicable law or regulation or would require any registration or licensing within such jurisdiction or to any us person i have read and understood the disclaimer set out above i understand that it may affect my rights and i agree to be bound by its terms by clicking on the “i agree” button i confirm that i am permitted to proceed to electronic versions of these materials we use cookies to give you the best experience on our website if you continue without changing your cookie settings we assume that you consent to our use of cookies on this device you can change your cookie settings at any time but if you do you may lose some functionality on our website more information can be found in our cookie policy close malin corp plc company profile  bloomberg feedback malin corp plc public company company profile sector health care industry biotech  pharma subindustry biotech malin corporation plc is a global life sciences company focusing on the therapeutics devices and diagnostics space the company selects private life science companies to acquire and help reach success malin corporation operates in ireland corporate information address  harbour square crofton road dun laoghaire dun laoghaire ireland phone  fax  web url wwwmalinplccom board members chairman company kyran mclaughlin je davy holdings chief executive officer company g martin serenus biotherapeutics corp chief invsmt officerexec dir company adrian howd malin corp plc chief financial officer company darragh lyons malin corp plc board members company robert ingram hatteras venture partners sean murphy brandon point industries kieran mcgowan appian asset management ltd owen hughes intarcia therapeutics inc show more from the web press releases surgical specialty center of baton rouge is first hospital in southern louisiana to enhance patient safety by deploying a xenex jul   the new ireland fund inc monthly portfolio update jul   immunocore announces third oncology target selected in discovery collaboration with glaxosmithkline jul   ligand’s partner melinta therapeutics announces us fda approval of baxdela™ delafloxacin for acute bacterial skin and jun   melinta therapeutics announces us fda approval of baxdela™ delafloxacin for acute bacterial skin and skin structure infec jun   xenex announces lightstrike disinfection pod™  industrys first mobile equipment disinfection system jun   immunocore announces compelling single agent imcgp clinical data in metastatic uveal melanoma at asco  annual meeting jun   the new ireland fund inc monthly portfolio update jun   key executives g kelly martin chief executive officer darragh lyons chief financial officer adrian howd chief invsmt officerexec dir neil mcloughlin acting secretarygen cnsl fiona dunlevy headtax  corp affairs sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data mlcdublin stock quote  malin corp plc  bloomberg markets error could not add to watchlist x  watchlist malin corp plc mlcid dublin eur   as of  am edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share gbp ttm  market cap m eur  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  surgical specialty center of baton rouge is first hospital in southern louisiana to enhance patient safety by deploying a xenex  the new ireland fund inc monthly portfolio update  immunocore announces third oncology target selected in discovery collaboration with glaxosmithkline  ligand’s partner melinta therapeutics announces us fda approval of baxdela™ delafloxacin for acute bacterial skin and  melinta therapeutics announces us fda approval of baxdela™ delafloxacin for acute bacterial skin and skin structure infec  xenex announces lightstrike disinfection pod™  industrys first mobile equipment disinfection system  immunocore announces compelling single agent imcgp clinical data in metastatic uveal melanoma at asco  annual meeting  the new ireland fund inc monthly portfolio update  immunocore highlights imcgp clinical data in uveal melanoma at asco  annual meeting  robert a ingram named chairman of biocryst pharmaceuticals inc there are currently no press releases for this ticker please check back later profile malin corporation plc is a global life sciences company focusing on the therapeutics devices and diagnostics space the company selects private life science companies to acquire and help reach success malin corporation operates in ireland address  harbour squarecrofton roaddun laoghairedun laoghaire ireland phone  website wwwmalinplccom executives board members g kelly martin chief executive officer darragh lyons chief financial officer adrian howd chief invsmt officerexec dir neil mcloughlin acting secretarygen cnsl fiona dunlevy headtax  corp affairs show more malin plc » directors menu homeaboutdirectorsboard committeesadvisorsbusinessesdmedicalaltan pharmaanh discoveryartizan biosciencescilatus biopharmahatteras venture partners hvpimmunocorejaan healthknow biokymabmelinta therapeuticsneuvtnovanposeida therapeuticsserenusviamet pharmaceuticalswren therapeuticsxenex disinfection servicesnewsmalin rns announcementsinvestee company newsinvestorsshareholder centrereports  resultspfic statusesm rule corporate governance  constitutional documentsinvestor relations contactanalyst coveragecontact directors the board of malin corporation plc is comprised of  directors of whom  have executive functions chairman kyran mclaughlin chief executive officer kelly martin chief investment officer adrian howd phd chief financial officer darragh lyons lead independent nonexecutive director liam daniel independent nonexecutive director owen hughes independent nonexecutive director robert a ingram independent nonexecutive director kieran mcgowan independent nonexecutive director donal o’connor profiles of the individual directors are set out below kyran mclaughlin — chairman mr mclaughlin is currently deputy chairman and head of capital markets at davy and holds a number of public and private company directorships including ryanair plc mr mclaughlin is also a past director of elan from december  to its sale to perrigo company in december  and was chairman of elan from january  to january  kelly martin — chief executive officer kelly martin served as ceo of elan ireland’s largest indigenous biotech company from february  until its successful sale to perrigo company in december  before joining elan mr martin spent more than  years at merrill lynch  co inc where he held a broad array of operating and executive responsibilities mr martin also serves as a nonexecutive director on a number of public and private company boards mr martin is a cofounder and nonexecutive director of bpi adrian howd phd — chief investment officer dr adrian howd has held both sellside and buyside roles being a highly ranked sellside analyst at berenberg nomura and abn amro where he was global head of healthcare research he also gained buyside experience running a healthcare portfolio as part of the principal strategies group at abn amro dr howd also served as executive vice president head of neuroscience and corporate development at evotec ag dr howd has a phd in molecular neuroscience from the university of london dr howd is a nonexecutive director of bpi darragh lyons — chief financial officer darragh lyons is a chartered accountant and worked in a number of senior finance positions in elan most recently serving as the head of group finance prior to the sale of elan to perrigo where he was responsible for all aspects of internal and external reporting as well as overseeing the transactional and financing activities of the company prior to joining elan mr lyons worked with pricewaterhousecoopers in dublin the united states and canada and also served in the firm’s global technical accounting group liam daniel — lead independent nonexecutive director liam daniel is a nonexecutive director of horizon pharma plc since september  and was president of the institute of directors in ireland from  to  having been elected to the board of that institute in june  he served with elan from  until  in various roles including controller company secretary executive vice president and as an executive director following elan’s acquisition by perrigo company in december  mr daniel retired from elan in march  he is a graduate of university college dublin a fellow of chartered accountants ireland and a chartered director owen hughes — independent nonexecutive director owen hughes currently serves as the chief business officer and head of corporate development at intarcia therapeutics a late stage diabetes company and as a director of radius health a phase  osteoporosis company prior to intarcia mr hughes served as a director at brookside capital a multibillion dollar hedge fund that falls under the bain capital umbrella there he comanaged public and private healthcare investments including those in the biotechnology medtech and services segments mr hughes has over  years of wall street experience on both the buy and sellside robert a ingram — independent nonexecutive director robert ingram is the former ceochairman of glaxowellcome where he coled the merger and integration that formed glaxosmithkline the world’s second largest pharmaceutical company he currently serves as a general partner of hatteras venture partners he previously served as chairman of elan from  until its sale to perrigo company in december  mr ingram was asked by former us president george hw bush to form and chair the ceo roundtable on cancer and he was awarded the martin luther king jr legacy award for international service in january  kieran mcgowan — independent nonexecutive director kieran mcgowan is currently chairman of appian asset management from  until his retirement in december  mr mcgowan was chief executive of the industrial development authority of ireland up until may  he was chairman of crh plc and has sat on the board of a number of private companies he is a director of charles schwab worldwide funds plc mr mcgowan is also a past director of elan corporation plc from december  to its sale to perrigo company in december  he has served as president of the irish management institute and has chaired the governing authority at university college dublin mr mcgowan is also a member of the panel of scientific and corporate advisory partners of bpi donal o’connor — independent nonexecutive director donal o’connor is currently a nonexecutive director of perrigo company plc and theravance biopharma inc mr o’connor previously held a number of positions at partner level in pricewaterhouse coopers pwc ireland including serving as senior partner from  until  he also served as a member of pwc global board from  to  in this section directors board committees advisors we use cookies to give you the best experience on our website if you continue without changing your cookie settings we assume that you consent to our use of cookies on this device you can change your cookie settings at any time but if you do you may lose some functionality on our website more information can be found in our cookie policy close esm schedule   malin corp plc irsh  rns company announcements  equities  fe trustnet trustnet login to continue using this website please tell us a little about yourself i am a financial adviser i am a discretionary fund manager  multimanager i am a financial paraplanner i work in financial services i am a private investor this site uses cookies some of the cookies are essential for parts of the site to operate and have already been set you may delete and block all cookies from this site but if you do parts of the site may not work to find out more about cookies on the website and how to delete cookies see our privacy and cookie policy i accept the fe trustnet cookie policy continue for more information click here investments unit trusts  oeics unit trusts  oeics home prices  performance multimanager  mixed asset special reports utoeic ratings az fund factsheets az group factsheets az sectors funds guide most viewed funds most viewed groups ia unit trusts  oeics ia unit trusts  oeics home prices  performance multimanager  mixed asset special reports ia utoeic ratings az fund factsheets az group factsheets az sectors funds guide most viewed funds most viewed groups equities equities home prices  performance az equity factsheets latest announcements investment trusts investment trusts home prices  performance investment trust ratings az investment trust factsheets az group factsheets az warrants az sectors split capital analytics investment trust guide most viewed investment trusts most viewed groups pensions pensions home prices  performance pension fund ratings az pension fund factsheets az group factsheets az pension product factsheets az sectors most viewed funds most viewed groups life life home prices  performance az life fund ratings az life fund factsheets az life group factsheets az life product factsheets az sectors life insurance glossary most viewed funds most viewed groups offshore funds offshore funds home prices  performance offshore fund ratings az offshore fund factsheets az group factsheets az sectors offshore funds guide most viewed funds most viewed groups etfs etfs home etf prices  performance etf fund ratings az etf factsheets az group factsheets az sectors etfs guide most viewed funds most viewed groups vcts vcts home vct prices  performance az vct factsheets vcts guide most viewed funds most viewed groups structured products structured products home az structured product factsheets az group factsheets structured products guide structured products glossary fund managers fund managers home alpha managers league table az manager factsheets news  research news  research home news archive education guides education guides home emerging market etfs unit trust  oeic investment trust offshore funds isas fe trustnet videos brighttalk videos learning learn about investing investment basics pensions investing in a fund investment trusts exchange traded funds etfs passive funds and trackers what is an isa what to invest in bonds equities property commodities where to invest uk us europe emerging markets asia how to invest setting objectives for your portfolio asset allocation  the basics measuring performance onshore and offshore  what’s the difference fund ratings about fe ratings fe crown fund ratings fe passive fund ratings fe alpha manager ratings fe risk scores the adviser fund index portfolio portfolio home watchlist alerts tools home fundswire fundswire home manage my alerts charting find an ifa pension calculator ifa tools ifa tools home fe afi client fund profiler structured products whitelabel factsheets passive fundsnew passive funds homepage sectors uk equities north american equities european equities japanese equities emerging market equities uk gilts property sterling corporate bonds indexlinked gilts reading list clear all list  your basket aberdeen global indian equity d gbp open basket login select account login remember me password reminder not registered click here register      choose a user type i am a financial adviser i am a discretionary fund manager  multimanager i am a financial paraplanner i work in financial services i am a private investor  i accept your terms of use send me fe trustnet bulletins register its look like youre leaving us what would you like us to do with the funds youve selected show me all my options forget them save them remember my choice customise this table company epictidm sedolisin share tweet   print      rss malin corp plc irsh malin corp plc esm schedule  rns number  g malin corporation plc  february    ﻿   preadmission announcementesm schedule  announcement to be made by the esm applicant prior to admission in accordance with rule  of the esm rules for companies all applicants must complete the following company name malin corporation plc malin or the company company registered address and if different company trading address including postcodes  harbour square crofton road dun laoghaire co dublin ireland country of incorporation ireland company website address containing all information required by rule  in the esm rules for companies wwwmalinplccom from admission company business including main country of operation or in the case of an investing company details of its investing strategy if the admission is sought as a result of a reverse takeover under rule  of the esm rules for companies this should be stated malin is a newly established irish incorporated public limited company its purpose is to create shareholder value through the selective longterm application of capital and operational expertise to private preipo pretrade sale operating businesses in dynamic and fast growing segments of the life sciences industry malin will focus its efforts on acquiring majority or significant minority equity positions in companies with post investment valuations in the  million to  million range and post acquisition on building optimal long term value malin intends to build a stable of assets across the life science sector and will broadly categorise its interest in the life sciences industry across therapeutics devices and diagnostic market segments the company has already entered into acquisition and investment agreements or binding heads of agreement with seven companies initial acquisitions and investments which meet its criteria with total committed expenditure in respect of these initial acquisitions and investments of approximately € million with a further amount of up to approximately € million of followon investment options or investments subject to contingent commitments it is intended that the initial acquisitions and investments will be completed as soon as practicable following admission malin will also seek to make a number of further acquisitions and investments post its flotation   the following is a broad overview of the assets being acquired as part of the initial acquisitions and investments ·      viamet a novel small molecule drug development platform targeting metalloenzymes therapeutic applications include dermatology womens health and multiple orphanrare diseases fellow shareholders include novartis venture fund lilly ventures and woodford investment management ·      kymab a spinout from the wellcome trust sanger institute in cambridge uk focused on the development of a broad pipeline of fully human monoclonal antibody therapeutics via its proprietary kymouse™ platform current investors are the bill and melinda gates foundation and the wellcome trust ·      novan a nitric oxide based drug development platform with broad therapeutic applications lead product candidate is in latestage clinical development in the field of dermatology additional applications may include infectious disease and oncology ·      xenex a marketed nextgeneration automated robotic disinfection device effective against a wide range of bacteria and viruses associated with hospital acquired infections the recent ebola virus outbreak has increased demand for more effective disinfection systems  ·      emba medical a novel vascular embolisation system device regulatory filings for lead product in us expected q  and in eu in q  fellow shareholders include woodford investment management ·      anh discovery an innovative drug discovery company targeting ubiquitin proteasome pathway system ups dysfunction implicated in cancers neurodegenerative metabolic and cardiovascular diseases ·     serenus a pan african biopharmaceutical commercial and distribution platform capabilities will include targeted and specific latestage drug development as well as broad inlicensing registration and commercialisation of therapies approved in other territories malins head office is in dublin ireland with subsidiary offices located in new haven connecticut and durham research triangle north carolina usa details of securities to be admitted including any restrictions as to transfer of securities ie where known number of shares nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares the total number of ordinary shares of nominal value € each ordinary shares to be admitted to esm is tbc the issue price of each ordinary share is € there are no shares to be held in treasury there are no restrictions on the transfer of securities to be admitted capital to be raised on admission if applicable and anticipated market capitalisation on admission between € million and € million is to be raised on admission through the placing of tbc new ordinary shares the anticipated market capitalisation of the company on admission is tbc a substantial portion of the capital has been committed and will be disclosed in malins intention to float announcement in the coming days   percentage of esm securities not in public hands on admission tbc details of any other exchange or trading platform to which securities or other securities of the company are or will be admitted or traded na full names and functions of directors and proposed directors underlining the first name by which each is known or including any other name by which each is known john given   nonexecutive chairman dr adrian graham howd   chief executive officer darragh fergal lyons   chief financial officer george kelly martin   nonexecutive director sean edward murphy   nonexecutive director robert alexander ingram   nonexecutive director william liam francis daniel   lead independent nonexecutive director owen patrick hughes jr independent nonexecutive director kieran mcgowan   nonexecutive director full names and holdings of significant shareholders expressed as a percentage of the issued share capital before or after admission underlining the first name by which each is known or including any other name by which each is known before admission   name  issued share capital brandon point enterprises  limited                                      after admission   tbc   names of all persons to be disclosed in accordance with schedule two paragraph h of the esm rules for companies na   i       anticipated accounting reference date  december ii      date to which the main financial information in the admission document has been prepared  december  iii     dates by which it must publish its first three reports pursuant to rules  and  in the esm rules for companies a  september  in respect of  months ended  june  b  june  in respect of year ended  december  and c  september  in respect of  months ended  june  expected admission date march  name and address of esm adviser   davy corporate finance davy house  dawson street dublin  ireland name and address of broker   davy davy house  dawson street dublin  ireland other than in the case of a quoted applicant details of where postal or internet address the admission document will be available from with a statement that this will contain full details about the applicant and the admission of its securities copies of the admission document will be available for download at wwwmalinplccom  from the date of admission the admission document will contain full details about the applicant and the admission of its securities date of notification  february  newupdate see note new   this information is provided by rnsthe company news service from the london stock exchange  end  mscpguwupupapwq quick links equity home equity prices and performance latest announcements our product portfolio wwwtrustnetcom wwwtrustnetoffshorecom wwwtrustnetmiddleeastcom   wwwinvestegatecouk wwwfundlistingscom fe analytics   data feeds factsheet and literature production webtools data provided by fe care has been taken to ensure that the information is correct but fe neither warrants represents nor guarantees the contents of information nor does it accept any responsibility for errors inaccuracies omissions or any inconsistencies herein past performance does not predict future performance it should not be the main or sole reason for making an investment decision the value of investments and any income from them can fall as well as rise login help contact us for equity investors fe investegate for private investors trustnet direct for professional investors fe invest fe analytics fe data feeds fe fund listings for international investors fe trustnet hong kong fe trustnet offshore fe trustnet middle east quick links trustnetmagazine investment research fe trustnet videos top rated funds top performing funds find a fund build a portfolio the uk’s best fund managers performance charting about us fund performance ia unit trusts  oeics equities investment trusts pension funds life funds offshore funds etfs venture capital trusts stay connected with fe trustnet trustnet mobile website latest  five reasons to keep hold of your defensive funds   monday january   you are currently using an old browser which will not be supported by trustnet after  to ensure you benefit from all features on the site please update your browser   close  trustnet limited  all rights reserved please read our terms of use  disclaimer and privacy and cookie policy data supplied in conjunction with thomson financial limited london stock exchange plc structuredretailproductscom and manorparkcom malin corporation plc mlcmi people  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states malin corporation plc mlcmi related topics stocksstock screenermarket datahealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse mlcmi on irish stock exchange eur am edt change  chg €  prev close € open € days high € days low € volume  avg vol  wk high € wk low € summary name age since current position kyran mclaughlin   nonexecutive chairman of the board adrian howd  chief executive officer executive director darragh lyons  chief financial officer executive director neil mcloughlin general counsel company secretary david dobrosky senior analyst fiona dunlevy head of tax and corporate affairs peter schwartzman  member of senior management team owen hughes  nonexecutive director robert ingram  nonexecutive director g kelly martin  nonexecutive director kieran mcgowan  nonexecutive director donal oconnor   nonexecutive director liam daniel  lead independent nonexecutive director » insider trading biographies name description kyran mclaughlin mr kyran mclaughlin has been appointed as a nonexecutive chairman of the board of the company with effect from  december  mr mclaughlin is currently deputy chairman and head of capital markets at davy and holds a number of public and private company directorships adrian howd mr adrian howd phd is chief executive officer executive director of the company he held both sellside and buyside roles being a highly ranked sellside analyst at berenberg nomura and abn amro where he was global head of healthcare research he also gained buyside experience running a healthcare portfolio as part of the principal strategies group at abn amro dr howd also served as executive vice president head of neuroscience and corporate development at evotec ag dr howd has a phd in molecular neuroscience from the university of london dr howd is a principal director and shareholder of bpi darragh lyons mr darragh lyons is chief financial officer executive director of the company he is a chartered accountant and worked in a number of senior finance positions in elan most recently serving as the head of group finance prior to the sale of elan to perrigo where he was responsible for all aspects of internal and external reporting as well as overseeing the transactional and financing activities of the company prior to joining elan mr lyons worked with pricewaterhousecoopers in dublin the united states and canada and also served in the firm’s global technical accounting group he is a director of bpms neil mcloughlin mr neil mcloughlin is acting as a general counsel and company secretary of the company he is a barrister and a fellow of the institute of chartered company secretaries he spent almost ten years at elan where he was responsible for a wide range of business critical functions and most recently served as associate general counsel  assistant secretary prior to joining elan mr mcloughlin worked at bdo simpson xavier where he specialised in corporate restructuring he is also head of legal and transactions with bpi david dobrosky mr david dobrosky is senior analyst of the company he is a former senior analyst in the investment grade bond division of bank of america merrill lynch and a graduate of harvard college he is also a senior analyst with bpi fiona dunlevy ms fiona dunlevy is head of tax and corporate affairs of the company she is a chartered accountant and chartered tax adviser she is the former tax director at elan where she played a pivotal role in the spinoff of the prothena business division restructuring of the tysabri collaboration and the ultimate sale of the elan group to perrigo company prior to joining elan ms dunlevy worked within deloittes international tax group in dublin and new york specialising in crossborder tax planning and ma tax structuring she is also head of tax with bpi peter schwartzman mr peter a schwartzman is the member of senior management team of the company he brings  years of experience in asset and risk management to malin he was most recently a managing director in the leveraged finance group within blackrock financial management  the worlds largest asset manager from  to  peter was a leading member of a team that managed over  billion of assets in credit markets peters initial focus in malin will be to work with and alongside a number of the current members of the senior team to further refine malins capital sourcing efforts and subsequently how that capital is structured a particular focus will center on aligning current and future capital to cash flow generating opportunities that may afford shareholders additional ways to participate in malins total shareholder return approach to capturing value he will report to malin ceo kelly martin and will be based in the companys offices in new haven connecticut usa peter has also previously held the role of vice president corporate bond research group at alliance capital management in addition to analyst roles in moodys investors service and jj kenny he holds an mba from new york university stern school of business owen hughes mr owen p hughes is nonexecutive director of the company he currently serves as the chief business officer and head of corporate development at intarcia therapeutics a late stage diabetes company and as a director of radius health a phase  osteoporosis company prior to intarcia mr hughes served as a director at brookside capital a multibillion dollar hedge fund that falls under the bain capital umbrella there he comanaged public and private healthcare investments including those in the biotechnology medtech and services segments mr hughes has over  years of wall street experience on both the buy and sellside robert ingram mr robert a ingram is nonexecutive director of the company he is the former ceochairman of glaxowellcome where he coled the merger and integration that formed glaxosmithkline the world’s second largest pharmaceutical company he currently serves as a general partner of hatteras venture partners he previously served as chairman of elan from  until its sale to perrigo company in december  mr ingram has numerous community and board engagements including lead directorship of valeant pharmaceuticals international and cree inc and membership on the board of directors of edwards lifesciences corporation and regeneron pharmaceuticals inc mr ingram was asked by former us president george hw bush to form and chair the ceo roundtable on cancer and he was awarded the martin luther king jr legacy award for international service in january  mr ingram is also a member of the panel of scientific and corporate advisory partners of bpi g kelly martin mr g kelly martin is nonexecutive director of the company he has been served as ceo of elan ireland’s largest indigenous biotech company from february  until its successful sale to perrigo company in december  before joining elan mr martin spent more than  years at merrill lynch  co inc where he held a broad array of operating and executive responsibilities mr martin also serves as a nonexecutive director on a number of public and private company boards mr martin is a cofounder director and shareholder of bpi kieran mcgowan mr kieran mcgowan is nonexecutive director of the company he is currently chairman of the public interest board of pwc and chairman of appian asset management from  until his retirement in december  mr mcgowan was chief executive of the industrial development authority of ireland up until may  he was chairman of crh plc and has sat on the board of a number of private companies he is a director of charles schwab worldwide funds plc mr mcgowan is also a past director of elan corporation plc from december  to its sale to perrigo company in december  he has served as president of the irish management institute and has chaired the governing authority at university college dublin mr mcgowan is also a member of the panel of scientific and corporate advisory partners of bpi donal oconnor mr donal oconnor is nonexecutive director of the company mr oconnor is currently a nonexecutive director of perrigo company plc and theravance biopharma inc mr oconnor previously held a number of positions at partner level in pricewaterhouse coopers pwc ireland including serving as senior partner from  until  he also served as a member of pwc global board from  to  liam daniel mr liam daniel is lead independent nonexecutive director of the company he has been nonexecutive director of horizon pharma plc since september  and president of the institute of directors in ireland since may  having been elected to the board of the institute of directors in ireland in june  he served with elan from  until  in various roles including controller company secretary executive vice president and as an executive director following elan’s acquisition by perrigo company in december  mr daniel retired from elan in march  he is a graduate of university college dublin a fellow of chartered accountants ireland and a chartered director basic compensation name fiscal year total kyran mclaughlin  adrian howd  darragh lyons  neil mcloughlin  david dobrosky  fiona dunlevy  peter schwartzman  owen hughes  robert ingram  g kelly martin  kieran mcgowan  donal oconnor  liam daniel  as of  options compensation name options value kyran mclaughlin   adrian howd   darragh lyons   neil mcloughlin   david dobrosky   fiona dunlevy   peter schwartzman   owen hughes   robert ingram   g kelly martin   kieran mcgowan   donal oconnor   liam daniel   insider trading » full list on insider trading related topics stocksstock screenermarket datahealthcarepharmaceuticals directorpdmr shareholding  malin corp plc   rns company announcements  equities  fe trustnet trustnet login to continue using this website please tell us a little about yourself i am a financial adviser i am a discretionary fund manager  multimanager i am a financial paraplanner i work in financial services i am a private investor this site uses cookies some of the cookies are essential for parts of the site to operate and have already been set you may delete and block all cookies from this site but if you do parts of the site may not work to find out more about cookies on the website and how to delete cookies see our privacy and cookie policy i accept the fe trustnet cookie policy continue for more information click here investments unit trusts  oeics unit trusts  oeics home prices  performance multimanager  mixed asset special reports utoeic ratings az fund factsheets az group factsheets az sectors funds guide most viewed funds most viewed groups ia unit trusts  oeics ia unit trusts  oeics home prices  performance multimanager  mixed asset special reports ia utoeic ratings az fund factsheets az group factsheets az sectors funds guide most viewed funds most viewed groups equities equities home prices  performance az equity factsheets latest announcements investment trusts investment trusts home prices  performance investment trust ratings az investment trust factsheets az group factsheets az warrants az sectors split capital analytics investment trust guide most viewed investment trusts most viewed groups pensions pensions home prices  performance pension fund ratings az pension fund factsheets az group factsheets az pension product factsheets az sectors most viewed funds most viewed groups life life home prices  performance az life fund ratings az life fund factsheets az life group factsheets az life product factsheets az sectors life insurance glossary most viewed funds most viewed groups offshore funds offshore funds home prices  performance offshore fund ratings az offshore fund factsheets az group factsheets az sectors offshore funds guide most viewed funds most viewed groups etfs etfs home etf prices  performance etf fund ratings az etf factsheets az group factsheets az sectors etfs guide most viewed funds most viewed groups vcts vcts home vct prices  performance az vct factsheets vcts guide most viewed funds most viewed groups structured products structured products home az structured product factsheets az group factsheets structured products guide structured products glossary fund managers fund managers home alpha managers league table az manager factsheets news  research news  research home news archive education guides education guides home emerging market etfs unit trust  oeic investment trust offshore funds isas fe trustnet videos brighttalk videos learning learn about investing investment basics pensions investing in a fund investment trusts exchange traded funds etfs passive funds and trackers what is an isa what to invest in bonds equities property commodities where to invest uk us europe emerging markets asia how to invest setting objectives for your portfolio asset allocation  the basics measuring performance onshore and offshore  what’s the difference fund ratings about fe ratings fe crown fund ratings fe passive fund ratings fe alpha manager ratings fe risk scores the adviser fund index portfolio portfolio home watchlist alerts tools home fundswire fundswire home manage my alerts charting find an ifa pension calculator ifa tools ifa tools home fe afi client fund profiler structured products whitelabel factsheets passive fundsnew passive funds homepage sectors uk equities north american equities european equities japanese equities emerging market equities uk gilts property sterling corporate bonds indexlinked gilts reading list clear all list  your basket aberdeen global indian equity d gbp open basket login select account login remember me password reminder not registered click here register      choose a user type i am a financial adviser i am a discretionary fund manager  multimanager i am a financial paraplanner i work in financial services i am a private investor  i accept your terms of use send me fe trustnet bulletins register its look like youre leaving us what would you like us to do with the funds youve selected show me all my options forget them save them remember my choice customise this table company epictidm sedolisin share tweet   print      rss malin corp plc  malin corp plc directorpdmr shareholding rns number  l malin corporation plc  july    malin corporation plc directorpdmr shareholding   notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them  details of the person discharging managerial responsibilitiesperson closely associated a name sean murphy  reason for the notification a positionstatus senior executive pdmr b initial notification amendment initial notification  details of the issuer emission allowance market participant auction platform auctioneer or auction monitor a name malin corporation plc b lei jgysduuyu  details of the transactions section to be repeated for i each type of instrument ii each type of transaction iii each date and iv each place where transactions have been conducted a description of the financial instrument type of instrument identification code restriced share units rsus over ordinary shares of € each in malin corporation plc   identification code for malin corporation plc ordinary shares  iebvgc b nature of the transaction vesting of rsus under the malin corporation plc  long term incentive plan c prices and volumes prices volumes €      d aggregated information  aggregated volume  price not applicable  single transaction e date of the transaction  f place of the transaction outside of a trading venue   the ordinary shares vested on  july  at a price of € being the closing share price of the companys ordinary shares on the esm market of the irish stock exchange on friday  july    this information is provided by rnsthe company news service from the london stock exchange  end  dshrbmftmbttbmr quick links equity home equity prices and performance latest announcements our product portfolio wwwtrustnetcom wwwtrustnetoffshorecom wwwtrustnetmiddleeastcom   wwwinvestegatecouk wwwfundlistingscom fe analytics   data feeds factsheet and literature production webtools data provided by fe care has been taken to ensure that the information is correct but fe neither warrants represents nor guarantees the contents of information nor does it accept any responsibility for errors inaccuracies omissions or any inconsistencies herein past performance does not predict future performance it should not be the main or sole reason for making an investment decision the value of investments and any income from them can fall as well as rise login help contact us for equity investors fe investegate for private investors trustnet direct for professional investors fe invest fe analytics fe data feeds fe fund listings for international investors fe trustnet hong kong fe trustnet offshore fe trustnet middle east quick links trustnetmagazine investment research fe trustnet videos top rated funds top performing funds find a fund build a portfolio the uk’s best fund managers performance charting about us fund performance ia unit trusts  oeics equities investment trusts pension funds life funds offshore funds etfs venture capital trusts stay connected with fe trustnet trustnet mobile website latest  five reasons to keep hold of your defensive funds   monday january   you are currently using an old browser which will not be supported by trustnet after  to ensure you benefit from all features on the site please update your browser   close  trustnet limited  all rights reserved please read our terms of use  disclaimer and privacy and cookie policy data supplied in conjunction with thomson financial limited london stock exchange plc structuredretailproductscom and manorparkcom mlcie stock price  news  malin corp plc  wall street journal dow jones a news corp company news corp is a network of leading companies in the worlds of diversified media news education and information services dow jones barrons bigcharts djx dow jones newswires factiva financial news mansion global marketwatch newsmart newsplus private markets risk  compliance wsjcom wsj pro wsj conference wsj video news corp big decisions business spectator checkout harper collins new york post proptiger rea realtorcom storyful the australian the sun the times djia futures ▲     sp  f ▲     stoxx  ▲     us  yr ▲  yield    crude oil ▲     euro ▲     subscribe now sign in the wall street journal us edition us asia europe india  china  japan july   todays paper sections my journal home world us politics economy business tech markets opinion arts life real estate todays paper show all sections hide all sections world home africa asia canada china europe latin america middle east economy world video us home economy law new york politics real time economics washington wire journal report us video whats news podcast politics home washington wire politics video wsjnbc news poll economy home real time economics economic forecasting survey economy video business home management techwsjd aerospace  defense autos  transportation commercial real estate consumer products energy entrepreneurship financial services food  services health care hospitality law manufacturing media  marketing natural resources retail cfo journal cio journal cmo today logistics report risk  compliance heard on the street business video journal report business podcast tech home cio journal geoffrey fowler christopher mims joanna stern li yuan billion dollar startup club tech video tech podcast startup stock trader markets home bonds commercial real estate commodities  futures currencies deals financial services funds stocks your money heard on the street moneybeat wealth adviser ahead of the tape cfo journal journal report market data markets video markets podcast moneybeat podcast watching your wealth podcast opinion home james freeman william a galston daniel henninger holman w jenkins william mcgurn peggy noonan mary anastasia ogrady jason riley kimberley a strassel books film television theater art masterpiece series music dance opera exhibition cultural commentary editorials commentary letters to the editor the weekend interview potomac watch podcast foreign edition podcast opinion video notable  quotable best of the web newsletter morning editorial report newsletter arts home books film television theater art masterpiece series arts video wsj magazine life home careers cars food  drink health ideas real estate science sports style  fashion travel life video wsj magazine wsj puzzles the future of everything real estate home commercial real estate house of the day mansion real estate video hide all sections aim higher reach further get the wall street journal  for  weeks subscribe now sign in reveal navigation options subscribe sign in malin corp plc mlc ireland dublin search view all companies  am ist  € eur   volume  volume   day avg vol   day range     week range        d  d  m  m ytd  y  y   advanced charting compare compare to benchmark djia sp  global dow nasdaq health carelife sciences compare to add open  prior close    day mlc  djia  russell k  health carelife sciences  overview overview profile financials income statement balance sheet cash flow research  ratings historical prices options advanced charting news malin corp plcmlc significant news only  dow jones newswires malin corporation raises eurm in placing dow jones newswires load more key stock data  pe ratio ttm the price to earnings pe ratio a key valuation measure is calculated by dividing the stocks most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing  month period earnings per share ttm a companys net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding market capitalization reflects the total market value of a company market cap is calculated by multiplying the number of shares outstanding by the stocks price for companies with multiple common share classes market capitalization includes both classes shares outstanding number of shares that are currently held by investors including restricted shares owned by the companys officers and insiders as well as those held by the public public float the number of shares in the hands of public investors and available to trade to calculate start with total shares outstanding and subtract the number of restricted shares restricted stock typically is that issued to company insiders with limits on when it may be traded dividend yield a companys dividend expressed as a percentage of its current stock price key stock data pe ratio ttm na eps ttm € market cap € m shares outstanding  m public float  m yield mlc has not issued dividends in more than  year latest dividend na exdividend date na  shares sold short the total number of shares of a security that have been sold short and not yet repurchased change from last percentage change in short interest from the previous report to the most recent report exchanges report short interest twice a month percent of float total short positions relative to the number of shares available to trade short interest  na  money flow uptickdowntick ratio money flow measures the relative buying and selling pressure on a stock based on the value of trades made on an uptick in price and the value of trades made on a downtick in price the updown ratio is calculated by dividing the value of uptick trades by the value of downtick trades net money flow is the value of uptick trades minus the value of downtick trades our calculations are based on comprehensive delayed quotes stock money flow na advertisement competitors mlc company change pe ttm nsci netscientific plc    ory oryzon genomics sa    onc oncimmune holdings plc    obd oxford biodynamics plc    more information on mlc competitor data provided by capital cube profile mlc malin corp plc is a global life sciences company it acquires majority or significant minority equity positions in private preinitial public offering and pretrade operating businesses in the life sciences industry particularly therapeutics devices and diagnostic  harbour square dublin dublin ireland website map employees  sector biotechnology sales or revenue  m industry health carelife sciences y sales change  fiscal year ends december  download reports kyran mclaughlin nonexecutive chairman g kelly martin chief executive officer  executive director neil mcloughlin chief operating officer darragh lyons chief financial officer  executive director more research  ratings malin corp plcmlc pershare earnings actuals and estimates quarterly annual mlc will report fy  earnings on false mlc will report q earnings on false actual analyst range consensus na na na na na na     na na na na q  estimate trends current €  month ago €  months ago € q  estimate trends current €  month ago €  months ago € fy  estimate trends current €  month ago €  months ago € fy  estimate trends current €  month ago €  months ago € more financials malin corp plcmlc quarterly annual net income   m m m jun  dec  jun  dec    m m m   dec  quarter trend net income growth  sales or revenue  m sales or revenue growth  ebitda  m  year trend net income growth  sales or revenue  m sales or revenue growth  ebitda  m more overview notes  data providers realtime us stock quotes reflect trades reported through nasdaq only international stock quotes are delayed as per exchange requirements indexes may be realtime or delayed refer to time stamps on index quote pages for information on delay times quote data except us stocks provided by six financial information data is provided as is for informational purposes only and is not intended for trading purposes six financial information a does not make any express or implied warranties of any kind regarding the data including without limitation any warranty of merchantability or fitness for a particular purpose or use and b shall not be liable for any errors incompleteness interruption or delay action taken in reliance on any data or for any damages resulting therefrom data may be intentionally delayed pursuant to supplier requirements all of the mutual fund and etf information contained in this display was supplied by lipper a thomson reuters company subject to the following copyright  thomson reuters all rights reserved any copying republication or redistribution of lipper content including by caching framing or similar means is expressly prohibited without the prior written consent of lipper lipper shall not be liable for any errors or delays in the content or for any actions taken in reliance thereon bond quotes are updated in realtime source tullett prebon currency quotes are updated in realtime source tullet prebon fundamental company data and analyst estimates provided by factset copyright factset research systems inc all rights reserved advertisement malin corporation plc mlcise summary  ftcom subscribe sign in menu search financial times myft search the ft search search the ft search close marketsmarkets dataequities financial timesclosesearch theftsearch equities malin corporation plcmlciseselect symbolirelandmlciseirish stock exchangeunited statesmllnfpnkgrey marketmalin corporation plcactionsadd to watchlistadd to portfolioadd an alertfinancialsfinancial servicesprice eurtodays change  shares traded year changebetadata delayed at least  minutes as of jul    bstmore ▼applycancelactionsadd to your watchlistsnew watchlistnamecanceladdadd to your portfolionew portfolionamecurrencyselect a currencyuk pound gbpargentinian nuevo peso arsaustralian dollar audbahraini dinar bhdbrunei dollar bndbrazilian real brlcanadian dollar cadchilean peso clpchinese yuan renminbi cnyczech koruna czkdanish krone dkkegyptian pound egpeuro eurfiji dollar fjdhong kong dollar hkdhungarian forint hufisraeli shekel ilsindian rupee inrindonesian rupiah idrjapanese yen jpykuwaiti dinar kwdsri lankan rupee lkrmoroccan dirham madmalaysian ringgit myrmexican new peso mxnnew zealand dollar nzdnorwegian krone nokomani rial omrperuvian new sol penpapua new guinean kina pgkphilippine peso phppakistani rupee pkrpolish new zloty plnrussian ruble rubsaudi riyal sarsolomon islands dollar sbdseychelles rupee scrsingapore dollar sgdsouth african rand zarrepublic of korean won krwswedish krona sekswiss franc chftongan paanga toptaiwan dollar twdthai baht thbturkish lira tryuae dirham aedvietnamese dong vndvanuatu vatu vuvsamoan tala wstfrench pacific franc xpfus dollar usdghana cedi ghsnigeria naira ngnukraine hryvnia uahkenya shilling kescancelcontinueyour alertsdoneyou must be a registered user to save alerts please sign in or register ddwmmyyycompar applycancelcomparisonsmake up to three selections then save of  selected of  selectedsuggested comparisonseco animal health group plcselcuk ecza deposu ticaret ve sanayi asinnate pharma sasanthera pharmaceuticals holding agvetoquinol saab science sazealand pharma aktieselskabetrecipharm ab publargenx nvmolecular partners agcamurus absaveclearkey statisticsas of last trade malin corporation plc mlcise traded at   below its week high of  set on aug  week rangetodayapr  aug  markit short selling activitylowmedhighopenhighlowbidofferprevious closeaverage volumekshares outstandingmfree floatmpe ttmmarket capm eureps ttm eurdata delayed at least  minutes as of jul    bstmore ▼ about the companymalin corporation plc is an irelandbased global life sciences company the companys businesses include dmedical which is a technology company altan which is an injectable drug company anh discovery limited which focuses on designing novel small molecule therapeutics emba medical limited which offers vascular embolization system emba neuro limited hatteras venture partners hvp which is a life sciences company immunocore which is a biotechnology company jaan health which is a healthcare mobile technology company kymab limited which is a biopharmaceutical company melinta therapeutics inc novan inc which is a clinical stage company poseida therapeutics inc which is a human therapeutics company and viamet pharmaceuticals inc which is a drug discovery company the company operates through subsidiaries and focuses on various therapeutic areas including dermatology antiinfective pain immunology oncology neurology anatomy and other areasft lexiconfor more information visit the ft lexiconlexicon on this pageexplore our toolsalertsdata archiveportfolioworld marketsequities screenerfunds overview  thomson reuters click for restrictions all markets data located on ftcom is subject to the ft terms  conditionsall content on ftcom is for your general information and use only and is not intended to address your particular requirements in particular the content does not constitute any form of advice recommendation representation endorsement or arrangement by ft and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisionsany information that you receive via ftcom is at best delayed intraday data and not real time share price information may be rounded updown and therefore not entirely accurate ft is not responsible for any use of content by you outside its scope as stated in the ft terms  conditions markit short selling activity  markit all rights reservedalthough markit has made every effort to ensure this data is correct nevertheless no guarantee is given to the accuracy or completeness any opinions or estimates expressed herein are those of markit on the date of preparation and are subject to change without notice however no such opinions or estimates constitute legal investment or other advice you must therefore seek independent legal investment or other appropriate advice from a suitably qualified andor authorised and regulated advisor prior to making any legal investment or other decision this is intended for information purposes only and is not intended as an offer or recommendation to buy sell or otherwise deal in securities welcome to the ftcom markets data we’re constantly improving and would like to hear from you provide feedback fe investegate malin corp plc announcements  malin corp plc directorpdmr shareholding we use cookies on our website if you continue to browse our website without taking any action we will assume that you are happy to receive all cookies from our website read more dismiss financial express holdings limited “we” “our” “us” and derivatives are committed to protecting and respecting your privacy this privacy policy together with our terms of use sets out the basis on which any personal data that we collect from you or that you provide to us will be processed by us relating to your use of any of the below websites “sites” feanalyticscom feinvestnet fetransmissioncom investegatecouk trustnethk trustnetoffshorecom trustnetmiddleeastcom for the purposes of the data protection act  the data controller is trustnet limited of nd floor golden house  great pulteney street london wf nn our nominated representative for the purpose of this act is kirsty witter what information do we collect about you we collect information about you when you register with us or use any of our websites  services part of the registration process may include entering personal details  details of your investments we may collect information about your computer including where available your operating system browser version domain name and ip address and details of the website that you came from in order to improve this site you confirm that all information you supply is accurate cookies in order to provide personalised services to and analyse site traffic we may use a cookie file which is stored on your browser or the hard drive of your computer some of the cookies we use are essential for the sites to operate and may be used to deliver you different content depending on the type of investor you are you can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies however if you use your browser settings to block all cookies including essential cookies you may not be able to access all or part of our sites unless you have adjusted your browser setting so that it will refuse cookies our system will issue cookies as soon as you visit our sites how we use information we store and use information you provide as follows to present content effectively to provide you with information products or services that you request from us or which may interest you tailored to your specific interests where you have consented to be contacted for such purposes to carry out our obligations arising from any contracts between you and us to enable you to participate in interactive features of our service when you choose to do so to notify you about changes to our service to improve our content by tracking group information that describes the habits usage patterns and demographics of our customers we may also send you emails to provide information and keep you up to date with developments on our sites it is our policy to have instructions on how to unsubscribe so that you will not receive any future emails you can change your email address at any time in order to provide support on the usage of our tools our support team need access to all information provided in relation to the tool we will not disclose your name email address or postal address or any data that could identify you to any third party without first receiving your permission however you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house or to investigators inspectors or agents appointed by them or to any person empowered to require such information by or under any legal enactment any information they may request or require relating to you or if relevant any of your clients you agree that we may pass on information obtained under money laundering legislation as we consider necessary to comply with reporting requirements under such legislation access to your information and correction we want to ensure that the personal information we hold about you is accurate and up to date you may ask us to correct or remove information that is inaccurate you have the right under data protection legislation to access information held about you if you wish to receive a copy of any personal information we hold please write to us at rd floor hollywood house church street east woking gu hj any access request may be subject to a fee of £ to meet our costs in providing you with details of the information we hold about you where we store your personal data the data that we collect from you may be transferred to and stored at a destination outside the european economic area “eea” it may be processed by staff operating outside the eea who work for us or for one of our suppliers such staff may be engaged in amongst other things the provision of support services by submitting your personal data you agree to this transfer storing and processing we will take all steps reasonably necessary including the use of encryption to ensure that your data is treated securely and in accordance with this privacy policy unfortunately the transmission of information via the internet is not completely secure although we will do our best to protect your personal data we cannot guarantee the security of your data transmitted to our sites any transmission is at your own risk you will not hold us responsible for any breach of security unless we have been negligent or in wilful default changes to our privacy policy any changes we make to our privacy policy in the future will be posted on this page and where appropriate notified to you by email other websites our sites contain links to other websites if you follow a link to any of these websites please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies please check these policies before you submit any personal data to these websites contact if you want more information or have any questions or comments relating to our privacy policy please email email protected in the first instance fe trustnet uk    fe trustnet offshore    fe trustnet hong kong    fe trustnet middle east    fe analytics    fe fundlistings  rss    about us    contact us    help company announcements company news fe trustnet fundswire todays announcements most read announcements announcements archive advanced search email address password register  login  information  x  enter a valid email address show me how to log in   forgot password keyword company epictidm sedolisin news price announcements fundamentals news article rss malin corp plc  add to alerts list   print      mail a friend wednesday  july  malin corp plc directorpdmr shareholding rns number  l malin corporation plc  july     july  malin corporation plc pdmrpca shareholding   notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them  details of the person discharging managerial responsibilitiesperson closely associated a name fiona dunlevy  reason for the notification a positionstatus head of tax pdmr b initial notification amendment initial notification  details of the issuer emission allowance market participant auction platform auctioneer or auction monitor a name malin corporation plc b lei jgysduuyu  details of the transactions section to be repeated for i each type of instrument ii each type of transaction iii each date and iv each place where transactions have been conducted a description of the financial instrument type of instrument identification code ordinary shares of € each in malin corporation plc   identification code for malin corporation plc ordinary shares  iebvgc b nature of the transaction sale of shares c prices and volumes prices volumes € €       d aggregated information  aggregated volume  price two transactions    € and € e date of the transaction   f place of the transaction esm market of irish stock exchange   this information is provided by rnsthe company news service from the london stock exchange  end  dshrlmftmbibbjr all intraday prices are subject to a delay of fifteen  minutes fe investegate takes no responsibility for the accuracy of the information within this site the announcements are supplied by the denoted source queries about the content of an announcement should be directed to the source fe investegate reserves the right to publish a filtered set of announcements nav emmept rule  and frn variable rate fix announcements are filtered from this site        financial express all rights reserved visit other fe websites go to website fe trustnet uk fe trustnet offshore fe trustnet hong kong fe trustnet middle east fe analytics fe fundlistings  close  to help us provide a better service please select the description which fits you best investor with a financial adviser or broker investor without a financial adviser or broker financial adviser market professional broker banker solicitor etc discretionary fund manager institutional investor close this window why are you asking me this question related instruments this website is for private investors only to continue using fe investegate please confirm that you are a private investor i am a private investor  i am not a private investor a private investor is a recipient of the information who meets all of the conditions set out below the recipient  obtains access to the information in a personal capacity  is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services  is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange regulatory authority professional association or recognised professional body  does not currently act in any capacity as an investment adviser whether or not they have at some time been qualified to do so  uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds  does not distribute republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes to continue to use fe investegate please confirm you are a private investor this website is only for private investors by using this site you agree to use the content for private use only please confirm that you are a private investor using the buttons below i am a private investor i am not a private investor a d v e r t i s e m e n t microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft velocionet velocionet next generation plcs small inexpensive easytouse plcs programmed with vbuilder the industries most innovative programming software free download store ace branch embedded simulators software vbuilder vfactory indusoft tutorials  items –  account ace powerful pocketsized plcs branch lots of io where you need it better smaller cheaper branch out lots of io distributed processing awesome plc software and its free  x  x  worlds smallest plc starting at  lowest cost plc anywhere gets io where its needed connect up to  units up to  io points io with full plc power embed subroutines in them all the benefits of ace plus introducing ace fits most anywhere tailored to your needs io options  io points  io points  io points analog input options  volts  mamps  volts termination options pluggable spring type larger screwtype relay optocoupled mounting options din rail bolt mount super strong adhesive made for motion every ace and branch plc includes stepping motor pulsed output up to khz high speed counter for pulse or quadrature inputs up to  khz servo control  led intensity control every digital output can produce it’s own pulsewidth modulation pwm signal as well as software counters ramps and pids programmed with software youll enjoy using  graphically program in flow charts andor ladder logic to rapidly create custom applications we simplified the instruction set our function set is comprehensive easy to use and powerful no hunting for features vbuilder’s layout keeps the tools and information you need in plain view warnings and errors are presented in real time so there are no surprises at build tag based plcs are easier to use than address based ones but typically cost hundreds of dollars our entire line starting at  is tag based innovative features we’ve developed some great features to help you get things done quicker and more reliably subroutines break projects up into manageable chunks and allow program reuse objects isolate data and create logic components to greatly improve development efficiency maintainability and reliability linked subroutines specify that multiple subroutines should use the same objects maybe you’ve got an initialization routine you’d like in one subroutine and a process you want in another they can share an object so you don’t have to pass data between the two view your data and create operator controls with awesome free hmi we’re serious about delivering the easiest to use most productive plc software we could go on about our features but seeing is believing so check out our vbuilder page vfactory page or download vbuilder and vfactory theyre free meet branch expansion has a vlink input port instead of usb expansions are otherwise physically identical to branch main your sensors and actuators are branched out your plc should branch with them branchs unique structure beats backplane and brick systems at getting io where it’s need helping you run shorter wires and keep an organized system smarter io expansion units have full plc processing power and memory vbuilder’s power shines with branch put subroutines inside of io units to focus processing where it’s most needed debug your entire branch system as a unit no need to debug one processor at a time lets you view realtime data for your entire system plc programming should be fun we’ve got engaging tutorials to get you up to speed on our plcs and more are on the way whether you’re new to plcs or just new to us we want your learning experience to be enjoyable the tutorials aren’t boring or difficult to follow we promise free connector tool for a limited time only we’re giving away a free connector tool with every order every order over  ships free  of our plcs qualify for free us standard shipping we also ship to canada and mexico for   satisfaction guarantee shop with confidence knowing that you are free to return any product for a full  days after purchase and receive a full refund choose your adventure about us  contact us  store  velocio networks  to   privacy policy  terms of service